kabutan

Modalis Therapeutics hits year-high on potent gene suppression in MD candidates

Tue Apr 28, 2026 1:20 pm JST Catalyst

Modalis Therapeutics Corporation <4883> surged to a new year-to-date high in the Tuesday afternoon session. The rally followed a midday announcement that its investigational treatments for myotonic dystrophy type 1 (DM1), "MDL-202," and facioscapulohumeral muscular dystrophy (FSHD), "MDL-103," demonstrated potent and sustained target gene suppression in preclinical studies.

The findings suggest these candidates could offer superior safety and efficacy compared to conventional gene therapy approaches. Modalis Therapeutics is scheduled to present the full data at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Boston, held from May 11 to 15. The prospect of clinical validation at a major international forum fueled significant investor appetite.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles